International Biotechnology Trust (IBT)

Category Sector Equity Biotechnology

This investment trust can be held in an Investment ISA, SIPP and Investment Account

Sell

640.00p

Buy

648.00p

arrow-down-0.982p (-0.15%)

Discount/Premium

-7.68%

Estimated NAV

695.381p

Prices updated at 20 May 2024, 16:08 BST

Prices minimum 15 mins delay

Prices in GBX

Investment objective

The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.

FTSE All-Share

0.16%

LSE

Important documents: Please ensure that you have read the Key Information Document/Technical Guide , Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.

	642.00
Launch date	06 May 1994
	641.02p - 638.76p
	704.00p - 548.00p
	703.35 as of 16 May 2024
Ongoing charge audited (%)	1.4
	1.62
	0.06
	4.01
	55,471.77
	37.59m
	241.33m
	111.94
	Semi-Annually
	£296.83m
	£264.02m
	-9.49
	-8.32
	-5.53
Fund comparative index	Nasdaq Biotechnology Index
	Daily
	0.05m
	0.33m
	GB0004559349

Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.